Clinical trial
Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
NCT07770841 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 12, 2026
- Completion date
- April 11, 2028
- Enrollment
- 450 (estimated)
- Sites
- 62
Conditions
As the registry lists them; a condition with its own page is linked.